英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
tortor查看　tortor　在百度字典中的解释百度英翻中〔查看〕
tortor查看　tortor　在Google字典中的解释Google英翻中〔查看〕
tortor查看　tortor　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Nonstatin Cholesterol Medications - NEXLIZET® NEXLETOL®
    NEXLIZET is a combination of 2 medicines, bempedoic acid and ezetimibe The bempedoic acid portion of NEXLIZET was studied in a large clinical trial on reducing heart attack and heart procedures, like stent placement or bypass surgery, in adults who were unable to take recommended statin treatment
  • NEXLIZET® NEXLETOL® CLEAR Outcomes Trial Information
    The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
  • Nexlizet Patient Tips: 7 things you should know - Drugs. com
    The bempedoic acid component of Nexlizet also reduces the risk of a heart attack or revascularization procedures in statin-intolerant patients with or at risk for cardiovascular disease
  • FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart . . .
    U S FDA approves broad new labels for Nexletol and Nexlizet to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
  • U. S. FDA Approves Broad New Labels for Esperion . . . - BioSpace
    U S FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
  • Nexlizet: Dosage, side effects, uses, interactions, cost, and . . .
    Dosage for reducing certain cardiovascular risks Nexlizet is approved to help reduce the risk of heart attack and coronary revascularization (a type of heart procedure) in certain adults
  • Nexlizet: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Nexlizet (bempedoic acid and ezetimibe) may be used to reduce LDL-C levels in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), alone or in combination with other LDL-C lowering therapies It should be used i
  • NEXLIZET® Clinical Trial Results - See How It Performed
    How can NEXLIZET help you? If you have been told by your doctor you are at risk for a major heart event and you are unable to take recommended statin treatment, NEXLIZET can help lower your risk of heart attack and heart procedures, like stent placement or bypass surgery
  • FDA Expands Bempedoic Acid Label to Include Primary . . .
    The US Food and Drug Administration on March 22, 2024, approved broad label expansions for bempedoic acid (Nexletol) and bempedoic acid with ezetimibe (Nexlizet) tablets to include indications for expanded LDL-C lowering in both primary and secondary prevention of cardiovascular (CV) risk, according to an announcement from manufacturer Esperion





中文字典-英文字典  2005-2009